• 1
    Caron HN. Kinderoncologie: Neuroblastoom. In: VoutePA., de KrakerJ, CaronH, editors. Houten: Bohn Stafleu Van Loghum, 1997: 232245.
  • 2
    de Kraker J, Hoefnagel CA, Caron H, et al. First line targeted radiotherapy, a new concept in the treatment of advanced stage neuroblastoma. Eur J Cancer. 1995; 31A: 600-602.
  • 3
    de Kraker J, Hoefnagel CA, Caron HN, Vos A, Bras J, Greve JC. Iodobenzylguanide-131 therapy as first choice in non-metastasized neuroblastoma [in Dutch]. Ned Tijdschr Geneeskd. 1996; 140: 1997-2000.
  • 4
    de Kraker J, Hoefnagel CA, Voute PA. 131 I-Meta-iodobenzylguanidine (MIBG)-de-novo in neuroblastoma Stage III and IV patients [pamphlet]. Amsterdam, Academic Medical Center: 1994.
  • 5
    Hoefnagel CA, Voute PA, de Kraker J, Valdes Olmos RA. [131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma. J Nucl Biol Med. 1991; 35: 202-206.
  • 6
    Hoefnagel CA, de Kraker J, Valdes Olmos RA, Voute PA. 131I-MIBG as a first-line treatment in high-risk neuroblastoma patients. Nucl Med Commun. 1994; 15: 712-717.
  • 7
    Hoefnagel CA, de Kraker J, Valdes Olmos RA, Voute PA. [131I]MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med. 1995; 39: 61-64.
  • 8
    Hor G, Maul FD, Kornhuber B, et al. Outcome of [131I]metaiodobenzylguanidine therapy of neuroblastoma: seven years after. J Nucl Biol Med. 1991; 35: 207-215.
  • 9
    Voute PA, Hoefnagel CA, de Kraker J. 131I-meta-iodobenzylguanidine in diagnosis and treatment of neuroblastoma. Bull Cancer. 1988; 75: 107-111.
  • 10
    Voute PA, Hoefnagel CA, de Kraker J, et al. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy. Prog Clin Biol Res. 1991; 366: 439-445.
  • 11
    Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med. 1998; 39: 679-688.
  • 12
    Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry [review]. Eur J Nucl Med. 1994; 21: 545559.
  • 13
    Wafelman AR, Hoefnagel CA, Maessen HJ, Maes RAA, Beijnen JH. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours. Eur J Nucl Med. 1997; 24: 544-552.
  • 14
    Wafelman AR, Hoefnagel CA, Beijnen JH. Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use. Nucl Med Commun. 1993; 14: 819-822.
  • 15
    Wafelman AR, Suchi R, Hoefnagel CA, Beijnen JH. Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice. Eur J Nucl Med. 1993; 20: 614-616.
  • 16
    de Vijlder J, Vulsma T. Hereditary metabolic disorders causing hypothyroidism. In: BravermanL, UtigerR, editors. Werner & Ingbar's the thyroid, a fundamental and clinical text. 8th ed. Sidney: Lipincott Williams & Wilkins, 2000: 733-742.
  • 17
    Crocker DG. Nuclear reactor accidents-the use of KI as a blocking agent against radioiodine uptake in the thyroid-a review [review]. Health Phys. 1984; 46: 1265-1279.
  • 18
    Nauman J, Wolff J. Iodide prophylaxis in Poland after the Chernobyl reactor accident: benefits and risks. Am J Med. 1993; 94: 524-532.
  • 19
    Nikiforov YE, Heffess CS, Korzenko AV, Fagin JA, Gnepp DR. Characteristics of follicular tumors and nonneoplastic thyroid lesions in children and adolescents exposed to radiation as a result of the Chernobyl disaster. Cancer. 1995; 76: 900-909.
  • 20
    Nishiyama K, Kozuka T, Higashihara T, Miyauchi K, Okagawa K. Acute radiation thyroiditis. Int J Radiat Oncol Biol Phys. 1996; 36: 1221-1224.
  • 21
    Shalet SM, Rosenstock JD, Beardwell CG, Pearson D, Jones PH. Thyroid dysfunction following external irradiation to the neck for Hodgkin's disease in childhood. Clin Radiol. 1977; 28: 511-515.
  • 22
    Healy JC, Shafford EA, Reznek RH, et al. Sonographic abnormalities of the thyroid gland following radiotherapy in survivors of childhood Hodgkin's disease. Br J Radiol. 1996; 69: 617-623.
  • 23
    Tell R, Sjodin H, Lundell G, Lewin F, Lewensohn R. Hypothyroidism after external radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 1997; 39: 303-308.
  • 24
    Glatstein E, McHardy-Young S, Brast N, Eltringham JR, Kriss JP. Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. J Clin Endocrinol Metab. 1971; 32: 833-841.
  • 25
    Schneider AB, Ron E, Lubin J, Stovall M, Gierlowski TC. Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab. 1993; 77: 362-369.
  • 26
    Dunn JA, De Groot LJ, Henneman G. The thyroid and its diseases, Chapter 2. 2000 [accessed July 1, 2001].
  • 27
    Ingbar SH. Autoregulation of the thyroid. Response to iodide excess and depletion. Mayo Clin Proc. 1972;47: 814-823.
  • 28
    Verger P, Aurengo A, Geoffroy B, Le Guen B. Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine: a review. Thyroid. 2001; 11: 353-360.
  • 29
    Wolff J. Excess iodide inhibits the thyroid by multiple mechanisms. Adv Exp Med Biol. 1989; 261: 211-244.
  • 30
    Garaventa A, Guerra P, Arrighini A, et al. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine. Cancer. 1991; 67: 922-928.
  • 31
    Picco P, Garaventa A, Claudiani F, Garibaldi L, Borrone C. Primary hypothyroidism and 131I-MIBG therapy in neuroblastoma [letter]. Lancet. 1993; 342: 57.
  • 32
    Picco P, Garaventa A, Claudiani F, et al. Primary hypothyroidism as a consequence of 131-I-metaiodobenzylguanidine treatment for children with neuroblastoma. Cancer. 1995; 76: 1662-1664.
  • 33
    Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours [review]. Eur J Nucl Med. 1994; 21: 561-581.
  • 34
    Wafelman AR, Hoefnagel CA, Maes RA, Beijnen JH. Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion. Nuklearmedizin. 1996; 35: 122-125.
  • 35
    de Vathaire F, Francois P, Schlumberger M, et al. Epidemiological evidence for a common mechanism for neuroblastoma and differentiated thyroid tumour. Br J Cancer. 1992; 65: 425-428.
  • 36
    Heidemann PH, Stubbe P, Schurnbrand P, Prindull G. Iodine-induced hypothyroidism and goiter following lipiodolTM lymphography. Eur J Pediatr. 1982; 138: 82-83.
  • 37
    Pisarev M, Gartner R. Autoregulatory actions of iodine. In: BravermanL, UtigerR, editors. Werner & Ingbar's the thyroid, a fundamental and clinical text. 8th ed. Sydney: Lippincott Williams & Wilkins, 2000: 85-90.
  • 38
    Roti E, Vagenakis A. Effect of excess iodide: clinical aspects. In: BravermanL, UtigerR, editors. Werner & Ingbar's the thyroid, a fundamental and clinical text. 8th ed. Sydney: Lippincott Williams & Wilkins, 2000: 316-329.
  • 39
    Grenier G, Van Sande J, Willems C, Neve P, Dumont JE. Effects of microtubule inhibitors and cytochalasin B on thyroid metabolism in vitro. Biochimie. 1975; 57: 337-341.
  • 40
    Massart C, Le Tellier C, Lucas C, Gibassier J, Leclech G, Nicol M. Effects of cisplatin on human thyrocytes in monolayer or follicle culture. J Mol Endocrinol. 1992; 8: 243-248.
  • 41
    Livesey EA, Brook CG. Thyroid dysfunction after radiotherapy and chemotherapy of brain tumours. Arch Dis Child. 1989; 64: 593-595.
  • 42
    Duntas LH. Subclinical hypothyroidism: a misnomer in search of a new name. Thyroid. 2001; 11: 361-362.
  • 43
    Roncari DA, Murthy VK. Effects of thyroid hormones on enzymes involved in fatty acid and glycerolipid synthesis. J Biol Chem. 1975; 250: 4134-4138.
  • 44
    Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab. 1999; 84: 4472-4479.
  • 45
    Rose SR. Cranial irradiation and central hypothyroidism. Trends Endocrinol Metab. 2001; 12: 97-104.